Indaptus Therapeutics Signs Securities Purchase Agreement With David Lazar
Dec 23, 2025, 17:23 GMT-5
Indaptus Therapeutics entered into a Securities Purchase Agreement to raise $6.0 million through a private placement of convertible preferred stock. The deal covers 300,000 shares of Series AA and 700,000 shares of Series AAA at $6.00 per share, convertible into a combined 111,000,000 common shares following stockholder approval. Proceeds will support operations, severance, and general corporate purposes. The purchaser also received a six-month right to participate for up to 25% of future equity offerings on the same terms.
Agreement type: Private placement of Series AA and Series AAA Convertible Preferred Stock
Counterparty: David Lazar
Signed / Effective: Dec 22 2025 / Dec 23 2025
Duration / Termination: At will
Reason: Raise capital for operations and corporate purposes
Original SEC Filing: Indaptus Therapeutics, Inc. [ INDP ] - 8-K - Dec. 23, 2025
